Update on Iterum Therapeutics’ Business Developments
Dublin and Chicago-based Iterum Therapeutics plc (Nasdaq: ITRM), a pioneering company in the development of advanced oral and intravenous antibiotics, is focusing on addressing the challenge of infections caused by multi-drug resistant pathogens. This innovation is crucial in both community and hospital environments. Today, the company shares notable updates on its progress and strategic initiatives.
Recent Developments in Market Access
One of the key areas of focus for Iterum is enhancing access to its flagship product, ORLYNVAH™. This antibiotic continues to gain traction, as evidenced by substantial increases in coverage across various health plans. The company is actively expanding its reimbursement footprint, ensuring that a growing number of prescriptions are approved without prior authorization barriers. Currently, nearly 25% of insured individuals in the U.S. now have coverage for ORLYNVAH™, reflecting a significant step toward broader acceptance and integration into standard healthcare practices.
Medicare Part D Coverage and Strategic Partnerships
Excitingly, Iterum has secured a rebate agreement with one of the leading Medicare Part D Pharmacy Benefit Managers. This development positions ORLYNVAH™ for inclusion in Medicare Advantage Prescription Drug and Medicare Prescription Drug formularies, with anticipated coverage commencing in early 2026. This milestone underscores Iterum’s commitment to making their products accessible to patients with urgent medical needs.
Engagement with Pharmacy Benefit Managers
In addition to expanding coverage, Iterum has taken proactive steps by submitting bids to major Pharmacy Benefit Managers for both commercial and government plans, aiming to establish long-term formulary positions this year and into early next year. This strategic move highlights Iterum's dedication to ensuring that healthcare providers can readily access its innovative therapies.
Expansion in Distribution Channels
Beyond market access, Iterum has reported an increased availability of ORLYNVAH™ through additional specialty distributors. Notably, the product is now stocked by Cencora (previously known as AmerisourceBergen), alongside McKesson. This accessibility allows healthcare professionals to obtain the product more directly, thus enhancing its utility within clinical settings.
Intellectual Property Developments
Innovative research continues as Iterum expands its patent estate. A significant development occurred when the European Patent Office indicated its intent to grant a patent for a new combination medication involving sulopenem. This patent, which covers a bilayer tablet formulation, is expected to be issued soon, with a validity projected until December 2039, thereby reinforcing Iterum’s intellectual property portfolio and enhancing its competitive edge in the market.
Commitment to Combatting Resistance
Iterum Therapeutics is unwavering in its mission to provide differentiated anti-infectives that address the global challenge posed by multi-drug resistant microorganisms. They are advancing sulopenem, a novel penem antibiotic that has shown superior effectiveness against numerous resistant bacterial strains. The development of both oral and intravenous formulations underlines Iterum’s dedication to significantly improving treatment options for those with serious bacterial infections.
About ORLYNVAH™ and Its Impact
ORLYNVAH™, designed specifically for the treatment of uncomplicated urinary tract infections, is a testament to Iterum's innovative approach. It exhibits robust activity against resistant strains, making it a valuable addition to the available treatments for infections that have become increasingly difficult to manage due to antibiotic resistance.
Frequently Asked Questions
What is the main focus of Iterum Therapeutics?
Iterum Therapeutics concentrates on developing advanced antibiotics to combat infections caused by multi-drug resistant pathogens.
What is ORLYNVAH™ used for?
ORLYNVAH™ is an antibiotic treatment for uncomplicated urinary tract infections caused by specific resistant bacteria.
How does Iterum plan to expand market access for ORLYNVAH™?
Iterum is expanding market access through partnerships with major Pharmacy Benefit Managers and increasing the number of covered lives.
What recent achievements has Iterum announced?
Iterum has secured agreements for Medicare Part D coverage and increased distribution availability through key specialty distributors.
When can we expect ORLYNVAH™ coverage under Medicare?
Coverage for ORLYNVAH™ under Medicare is anticipated to begin in early 2026.
